2022 World Conference on Lung Cancer (Posters)-P1.16-01. Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Pdf Summary

Researchers presented updated results from the CHRYSALIS trial, which evaluated the combination of amivantamab and lazertinib in treatment-naïve patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). The study was funded by Janssen Research & Development and conducted by a team of researchers from various institutions. The analysis included 20 efficacy-evaluable patients who had a median follow-up of 22.3 months.<br /><br />The results showed that the combination therapy demonstrated clinically significant and durable antitumor activity with a tolerable safety profile. All patients in the study had a confirmed partial response, resulting in an overall response rate of 100%. The median duration of response and median progression-free survival had not been reached at the time of analysis. <br /><br />The treatment-naïve cohort included patients with exon 19 deletion and patients with exon 21 L858R mutations in the EGFR gene. Additionally, 50% of the patients had co-mutations in the TP53 gene. Baseline circulating tumor DNA analysis detected mutations in JAK2/PIC3CA, EGFR, and MET amplification. Notably, activating EGFR mutations in plasma were observed to clear in all patients with detectable circulating tumor DNA at baseline.<br /><br />The safety profile of the combination therapy was consistent with prior reports, with most adverse events being grade 1 or 2 in severity. Rash-related adverse events were the most common and led to dose interruptions, reductions, and discontinuations in some patients. One patient experienced grade 3 pneumonitis/interstitial lung disease and discontinued treatment.<br /><br />The researchers concluded that amivantamab and lazertinib demonstrated significant and durable antitumor activity in treatment-naïve patients with EGFR-mutant NSCLC. The ongoing phase 3 MARIPOSA study is further investigating the combination therapy as frontline therapy in this patient population.

Asset Subtitle

Byoung Chul Cho, South Korea

Meta Tag

Speaker Byoung Chul Cho, South Korea

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

CHRYSALIS trial

amivantamab

lazertinib

EGFR-mutant non-small cell lung cancer

treatment-naïve patients

antitumor activity

safety profile

efficacy-evaluable patients

progression-free survival

MARIPOSA study